Stocks
Immunovant, Inc.IMVT
NASDAQHealthcareBiotechnology$28.41
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing monoclonal antibody therapies for autoimmune diseases, with its lead candidate, batoclimab, targeting neonatal Fc receptor-mediated IgG recycling. Investors track the stock for its potential in treating myasthenia gravis and thyroid eye disease, as well as its pipeline of next-generation anti-FcRn candidates.
52W Range: $18.74-$45.42
Congressional Interest in Immunovant, Inc. (IMVT)
No congressional trades have been disclosed for Immunovant, Inc. (IMVT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IMVT?
No congressional trades found for this stock.